Nenni, m. proteomic investigation of in-vitro antineoplastic effect of ankaferd hemostat with 2d gel electrophoresis and maldi-TOF/TOF-MS in HEPG2, CACO-2 and HT-29 cancer cells

One of the breakthroughs in life sciences has been accomplished through the completion of the human genome project. However, the compose of the entire genome map has also brought a tough task for scientists. This task is the characterization of human proteome. Proteomic investigations are studies of the analysis of proteomes that change at the molecular level. Oncoproteomic is a branch of proteomics where proteomic technologies involving protein interactions in cancer cells are used. Oncoproteomic studies are being conducted to provide better understanding of cancer pathogenesis, to develop new tumor biomarkers for diagnosis and to provide early detection and diagnosis of samples using proteomic profiles. Within the scope of this thesis, Caco-2 and HT-29 colon cancer and HepG2 liver cancer cell lines were treated at different times by Ankaferd Hemostat (ABS; Ankaferd Blood Stopper®). Comparative proteomic studies were performed on cells treated with ABS (treated, T group) and untreated cells (control, C group). In proteomic studies, image analysis studies were performed for proteins belonging to groups C and T separated by two dimensional gel electrophoresis. Proteins that differed quantitatively by at least 2-fold when compared to groups C and T were analyzed by MALDI-TOF/TOF-MS and identified by peptide sequencing studies. Identified proteins were scanned in databases such as Uniprot and SwissProt, its functions, gene names, protein-protein interactions. Through the database of String, the biological processes and pathways that the ABS has affected in cancer cells have been identified. Key words: Proteomics, Colon cancer, Liver cancer, Two dimensional (2D) gel electrophoresis, MALDI-TOF/TOF-MS, Protein interactions, Ankaferd Hemostat. This thesis was supported by TUBITAK Project No. 114S500 and Hacettepe University BAB Project No. 17656.